• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗安纳托利亚钝缘蜱分离株 HAO3 的分子特征,该基因与 Bm86 蜱疫苗抗原的同源。

Molecular characterization of HAO3, the homologue of the Bm86 tick vaccine antigen, from the Iranian isolate of Hyalomma anatolicum anatolicum.

机构信息

Department of Biotechnology, Razi Vaccine and Serum Research Institute (RVSRI), P.O. Box 31975/148, Karaj, Tehran, Iran.

出版信息

Exp Parasitol. 2013 Dec;135(4):726-34. doi: 10.1016/j.exppara.2010.06.020. Epub 2010 Jun 18.

DOI:10.1016/j.exppara.2010.06.020
PMID:20599993
Abstract

Hyalomma anatolicum anatolicum tick is widely distributed in many parts of Iran and while the commercial vaccines based on the application of midgut-derived recombinant Bm86 antigen are used for its control, limited information about the efficiency of this vaccination in Iran is available. Herein, with the final aim of evaluation of Bm86-based heterologous vaccination, as the primary step the Bm86 homologue of the H. a. anatolicum (Hao3) from an Iranian isolate was characterized and compared with the commercialized Bm86 and other Bm86 homologoue sequences available in GenBank. Our in silico predictions resulted in the identification of seven epidermal growth factor (EGF)-like domains, one hydrophobic transmembrane region, one leader sequence and several glycosylation sites within the structure of both Hao3 and Bm86 proteins, which suggested the pattern of extracellular membrane-bound glycoproteins with the role of regulation in cell growth for both proteins. Moreover, while the nucleotide and amino acid sequences corresponding to Bm86 homologue showed a high level of conservation among the Iranian isolates (Hao3, Hao3-1 and Hao3-2, more than 99%), the Hao3 amino acid sequence had a homology of around 89%, 64% and 65% with that of Indian, Australian and Argentinean isolates, respectively. This indicated a considerable variation between commercial Bm86 antigen and H. a. anatolicum Bm86-like protein of Iranian and Indian isolates. Taking together, these results imply that the efficiency of commercial Bm86-based vaccine against the Iranian H. a. anatolicum may be under the question and indicates the value of the development of Hao3-based recombinant vaccines and further planning for their in vivo evaluation.

摘要

安纳托利亚璃眼蜱分布广泛,在伊朗的许多地区都有发现。虽然已经有基于应用中肠衍生重组 Bm86 抗原的商业疫苗来控制该蜱,但关于这种疫苗在伊朗的有效性的信息有限。在此,为了评估基于 Bm86 的异源疫苗接种的效果,作为第一步,我们对来自伊朗分离株的 H. a. anatolicum(Hao3)的 Bm86 同源物进行了表征,并与商业化的 Bm86 和 GenBank 中可用的其他 Bm86 同源序列进行了比较。我们的计算机预测结果表明,Hao3 和 Bm86 蛋白结构中存在七个表皮生长因子 (EGF)-样结构域、一个疏水跨膜区、一个前导序列和几个糖基化位点,这表明这两种蛋白都属于细胞外膜结合糖蛋白,具有调节细胞生长的作用。此外,尽管与 Bm86 同源物相对应的核苷酸和氨基酸序列在伊朗分离株(Hao3、Hao3-1 和 Hao3-2)中表现出高度的保守性(超过 99%),但 Hao3 氨基酸序列与印度、澳大利亚和阿根廷分离株的同源性分别约为 89%、64%和 65%。这表明商业 Bm86 抗原与伊朗和印度分离株的 H. a. anatolicum 的 Bm86 样蛋白之间存在相当大的差异。总的来说,这些结果表明,针对伊朗 H. a. anatolicum 的商业 Bm86 疫苗的有效性可能存在问题,并表明开发基于 Hao3 的重组疫苗的价值,以及进一步规划其体内评估的价值。

相似文献

1
Molecular characterization of HAO3, the homologue of the Bm86 tick vaccine antigen, from the Iranian isolate of Hyalomma anatolicum anatolicum.伊朗安纳托利亚钝缘蜱分离株 HAO3 的分子特征,该基因与 Bm86 蜱疫苗抗原的同源。
Exp Parasitol. 2013 Dec;135(4):726-34. doi: 10.1016/j.exppara.2010.06.020. Epub 2010 Jun 18.
2
Molecular characterization of Bm86 gene orthologs from Hyalomma excavatum, Hyalomma dromedarii and Hyalomma marginatum marginatum and comparison with a vaccine candidate from Hyalomma scupense.从钝缘蜱、绵羊痒螨和边缘革蜱中鉴定 Bm86 基因的同源基因,并与来自扇头蜱的候选疫苗进行比较。
Vet Parasitol. 2012 Nov 23;190(1-2):230-40. doi: 10.1016/j.vetpar.2012.05.017. Epub 2012 May 23.
3
Cloning, expression and immunoprotective efficacy of rHaa86, the homologue of the Bm86 tick vaccine antigen, from Hyalomma anatolicum anatolicum.来自小亚璃眼蜱的Bm86蜱疫苗抗原同源物rHaa86的克隆、表达及免疫保护效力
Parasite Immunol. 2009 Mar;31(3):111-22. doi: 10.1111/j.1365-3024.2008.01082.x.
4
Expression of recombinant HAO3 from an Iranian isolate of Hyalomma anatolicum anatolicum in Pichia pastoris and evaluation of its antigenicity.来自伊朗安纳托利亚璃眼蜱分离株的重组HAO3在毕赤酵母中的表达及其抗原性评估。
Biologicals. 2012 Jan;40(1):72-8. doi: 10.1016/j.biologicals.2011.10.003. Epub 2011 Nov 12.
5
Identification of a synthetic peptide inducing cross-reactive antibodies binding to Rhipicephalus (Boophilus) decoloratus, Rhipicephalus (Boophilus) microplus, Hyalomma anatolicum anatolicum and Rhipicephalus appendiculatus BM86 homologues.鉴定一种合成肽,该肽诱导与 Rhipicephalus (Boophilus) decoloratus、Rhipicephalus (Boophilus) microplus、Hyalomma anatolicum anatolicum 和 Rhipicephalus appendiculatus BM86 同源物发生交叉反应的抗体。
Vaccine. 2009 Dec 10;28(1):261-9. doi: 10.1016/j.vaccine.2009.09.085. Epub 2009 Oct 4.
6
Efficacy of Rhipicephalus (Boophilus) microplus Bm86 against Hyalomma dromedarii and Amblyomma cajennense tick infestations in camels and cattle.Bm86 型蜱(Boophilus)微纤恙螨对骆驼和牛中革蜱属(Hyalomma)和扇头蜱属(Amblyomma)蜱的杀灭效果。
Vaccine. 2012 May 14;30(23):3453-8. doi: 10.1016/j.vaccine.2012.03.020. Epub 2012 Mar 22.
7
Efficacy of Hyalomma scupense (Hd86) antigen against Hyalomma excavatum and H. scupense tick infestations in cattle.长角血蜱(Hd86)抗原对牛长角血蜱和璃眼蜱侵袭的效果。
Vaccine. 2012 Nov 19;30(49):7084-9. doi: 10.1016/j.vaccine.2012.09.051. Epub 2012 Oct 2.
8
Efficacy of rHaa86, an orthologue of Bm86, against challenge infestations of Hyalomma anatolicum anatolicum.重组 Ha 抗原 86(rHaa86)对感染期土耳其钝缘蜱的功效。
Transbound Emerg Dis. 2010 Apr;57(1-2):96-102. doi: 10.1111/j.1865-1682.2010.01107.x.
9
Molecular characterization of Rhipicephalus (Boophilus) microplus Bm86 homologue from Haemaphysalis longicornis ticks.长角血蜱微小牛蜱Bm86同源物的分子特征分析
Vet Parasitol. 2007 May 15;146(1-2):148-57. doi: 10.1016/j.vetpar.2007.01.015. Epub 2007 Mar 23.
10
Progress in development of vaccine against Hyalomma anatolicum anatolicum-Indian scenario.抗小亚璃眼蜱(印度种)疫苗的研发进展——印度的情况
Vaccine. 2008 Dec 19;26 Suppl 6:G40-7. doi: 10.1016/j.vaccine.2008.09.067.